See how KISQALI works for people with HR+, HER2- stage 2 and 3 early breast cancer with high risk of coming back

WOMAN VO: If you're wondering how this KISQALI works, I'm here to help.

Like you, I have HR+, HER2- early breast cancer, with a high risk of coming back.

When I was first diagnosed, I had a lot of questions. A big one for me was, what does having hormone receptor positive cancer mean?

My doctor helped me understand that with this type of cancer hormones play a big part in cancer cell growth. Hormones, like estrogen, work with proteins called CDK 4 and CDK 6 to tell cancer cells to grow and divide.

Once I understood how hormones affected my cancer, my doctor and I discussed treatment options. My doctor explained that I would need a treatment that could help stop CDK 4/6 and estrogen. One type of treatment that addresses CDK 4/6 and estrogen is KISQALI plus an aromatase inhibitor. I had assumed that KISQALI was chemotherapy because that was the only type of cancer treatment that I knew.

When my doctor explained that KISQALI is a pill and is not chemotherapy, I was surprised. Chemotherapy is a systemic treatment that can affect the whole body. KISQALI is a targeted treatment called a CDK 4/6 inhibitor. CDK 4/6 are proteins that are commonly found at higher levels in cancer cells. KISQALI was designed to block the pathways that CDK 4/6 use during the process of cell division, and an aromatase inhibitor is used to help stop the effects of estrogen. By taking KISQALI plus an aromatase inhibitor you are addressing the risk of cancer coming back in two different ways with one treatment plan.

Learning more about my treatment helped me feel empowered. I hope that by sharing my experience you can feel informed as you begin your experience with KISQALI.